$26.09
0.38% yesterday
Nasdaq, Sep 27, 10:00 pm CET
ISIN
US28036F1057
Symbol
EWTX
Sector
Industry

Edgewise Therapeutics Inc Stock price

$26.09
+6.31 31.90% 1M
+8.13 45.27% 6M
+15.15 138.48% YTD
+19.99 327.70% 1Y
+8.14 45.35% 3Y
-3.91 13.03% 5Y
-3.91 13.03% 10Y
Nasdaq, Closing price Fri, Sep 27 2024
+0.10 0.38%
ISIN
US28036F1057
Symbol
EWTX
Sector
Industry

Key metrics

Market capitalization $2.44b
Enterprise Value $1.93b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 4.77
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-136.17m
Free Cash Flow (TTM) Free Cash Flow $-104.72m
Cash position $511.75m
EPS (TTM) EPS $-1.53
P/E forward negative
Short interest 12.19%
Show more

Is Edgewise Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Edgewise Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Edgewise Therapeutics Inc forecast:

6x Buy
100%

Analyst Opinions

6 Analysts have issued a Edgewise Therapeutics Inc forecast:

Buy
100%

Financial data from Edgewise Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
- -
-
100%
- Direct Costs 2.04 2.04
117% 117%
-
-2.04 -2.04
117% 117%
-
- Selling and Administrative Expenses 24 24
18% 18%
-
- Research and Development Expense 108 108
56% 56%
-
-134 -134
48% 48%
-
- Depreciation and Amortization 2.04 2.04
117% 117%
-
EBIT (Operating Income) EBIT -136 -136
49% 49%
-
Net Profit -116 -116
43% 43%
-

In millions USD.

Don't miss a Thing! We will send you all news about Edgewise Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Edgewise Therapeutics Inc Stock News

Positive
MarketBeat
2 days ago
Edgewise Therapeutics NASDAQ: EWTX is a small-cap pharmaceutical stock that has been all the rage recently. Shares are up 55% in the last three months and up 332% over the past 52 weeks.
Positive
MarketBeat
8 days ago
Edgewise Therapeutics NASDAQ: EWTX is up 50% in a single session and 450% from recent lows for a reason. Its novel, oral, selective treatment for obstructive hypertrophic cardiomyopathy did remarkably well in early trials.
Positive
The Motley Fool
8 days ago
Edgewise's EDG-7500 shows promise as a treatment for hypertrophic cardiomyopathy. This market is currently underserved, largely because many heart drugs can cause other cardiac problems.
More Edgewise Therapeutics Inc News

Company Profile

Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. Its platform utilizes custom-built throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases. The company was founded by Badreddin Edris, Alan Russel and Peter A. Thompson in 2017 and is headquartered in Boulder, CO.

Head office United States
CEO Kevin Koch
Employees 88
Founded 2017
Website www.edgewisetx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today